Product Information
TRI-SPRINTEC TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1234 per EA under NDC 00555901858. Its NADAC has been published 677 times since Nov 28, 2013.
FDA first approved this application on Dec 29, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555901858
Classification
Generic
Dosage Form
KIT
Effective Date
10/21/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA075808FDA Approved
12/29/2003
TE Code
AB
On Market Since
12/29/2003
Price Statistics
The NADAC for TRI-SPRINTEC TABLET has been published 677 times since Nov 28, 2013, and over the history we have for it it has declined 64.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1234 per EA |
|---|---|
| All-time high | $0.3811 (Apr 16, 2014) |
| All-time low | $0.1072 (Jul 17, 2024) |
| 52-week high | $0.1332 |
| 52-week low | $0.1234 |
| Median price | $0.1945 |
| Average price | $0.2167 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 677 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 12% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norgestimate and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-SPRINTEC TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-SPRINTEC TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.1234 per EA (NDC 00555901858), effective Nov 11, 2026.
How has the price of TRI-SPRINTEC TABLET changed over time?
Over the history we have for it, the NADAC for TRI-SPRINTEC TABLET has declined 64.3%. It has been tracked across 677 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRI-SPRINTEC TABLET?
Since Nov 28, 2013, the NADAC for TRI-SPRINTEC TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.3811 (Apr 16, 2014), with a median of $0.1945 per EA.
Are there cheaper alternatives to TRI-SPRINTEC TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TRI-LO-MARZIA TABLET, is $0.1085 per EA — about 12% below TRI-SPRINTEC TABLET.
Who manufactures TRI-SPRINTEC TABLET?
TRI-SPRINTEC TABLET (NDC 00555901858) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.